Retatrutide: New Gen of Weight Loss Research Peptides (COA 2nd Photo)

Description

Legal Disclaimer
This information has not been reviewed or endorsed by the US FDA. It is provided solely for educational and research purposes. Retatrutide is not approved for medical use, human consumption, or as a therapeutic treatment.

Product Details

• Quantity: 10mg per vial
• Purity: ≥99%, Rigorous third-party testing
• Packaging: Secure, sealed, and tamper-proof vials
• Source: Synthesized using advanced peptide synthesis techniques
• Note: This product is sold in lyophilized powder form and must be reconstituted before use.

Overview

A new generation in weight loss research peptides. Retatrutide is a cutting-edge triagonist peptide that simultaneously targets GLP-1, GIP, and glucagon receptors, making it a promising tool for metabolic and obesity research. Its multi-pathway activation sets it apart from traditional single-receptor agonists, offering researchers a more comprehensive model for studying weight regulation, glucose metabolism, and insulin sensitivity.

Research Specifics

• Metabolic Research: Scientists are studying Retatrutide to see how it affects energy use and appetite control.
• Obesity Studies: Early research shows it may help with weight loss and fat burning.
• Diabetes Research: Experts are exploring how Retatrutide influences insulin resistance and blood sugar balance.
• Lipid Metabolism: Researchers are investigating its possible role in cholesterol and fat processing.

Technical Specifications

• Molecular Formula: C187H291N45O59
• Purity: ≥99% (HPLC-verified)
• Form: Lyophilized powder
• Storage: Store at -20°C for long-term stability
• Solubility: Requires reconstitution with sterile bacteriostatic water or a suitable solvent before use

For more detailed information on the applications of Retatrutide:

1. https://www.nature.com/articles/s41591-024-03018-2
2. https://www.uab.edu/reporter/clinicaltrials/item/10233-a-phase-3-randomized-multicenter-open-label-study-to-investigate-the-efficacy-and-safety-of-retatrutide-once-weekly-compared-with-semaglutide-once-weekly-in-adult-participants-with-type-2-diabetes-and-inadequate-glycemic-control-with-metformin-wit
3. https://www.vcuhealth.org/news/retatrutide-wiped-out-fat-in-liver-of-obese-patients/

⚡ Enhance your research with Retatrutide today! Secure your supply before stock runs out.

🔗 Return to All Research Peptides